

## SURFACE ECG AND RISK OF SUDDEN DEATH

A. Bayés de Luna, A Bayés-Genís, J. Guindo, X. Viñolas, J. Cinca.  
Hospital Sant Pau. Barcelona, Spain.

Surface ECG may be extremely useful to identify patients at risk of sudden death. In this paper we will comment the ECG patterns markers of sudden death that are genetically related to alterations of ion channels. As a matter of fact, different mutations in the same gene (SCN5A) are responsible of different syndromes like long QT syndrome, Brugada syndrome, and Lenegre disease. This means that different ECG morphologies may be explained by different mutations in the same gene (table I).

### 1. Congenital long QT syndrome.

There are two syndromes, Jarvell and Lange-Nielsen syndrome<sup>1</sup> with congenital deafness is very rare, and the Romano Ward syndrome<sup>2</sup>, a little more frequent. These are genetically related syndromes that have an ECG morphology expressed as long QT and other abnormalities of repolarization that may trigger sudden death<sup>3</sup>. Genetic mutations in at least 7 variants of Romano-Ward syndrome and 3 of Jervell and Lange-Nielsen syndrome have been published. In some of them (JLN1 to JLN3) a good correlation with ECG has been reported<sup>4,5,6,7,8</sup>.

Table II shows the ECG alterations more frequently seen in congenital long QT syndrome, and in table III the diagnostic clues of the syndrome. The incidence of arrhythmias, especially of “Torsades de Pointes” type is higher in LQT<sub>1</sub> and LQT<sub>2</sub> but they are more dangerous in the LQT<sub>3</sub> type. Furthermore, arrhythmias are more related with physical activity in LQT<sub>1</sub> and with rest or sleep in LQT<sub>1</sub> and LQT<sub>3</sub><sup>8</sup>.

### 2. Hypertrophic cardiomyopathy

It is also a genetic disease characterized by hypertrophy, especially of left ventricle and disarray of myocardial fibers. At least 9 mutations including troponin and  $\beta$  myosin heavy chain mutations have been described. Patients with mutations of troponin-T present more disarray and sudden death in young people and less hypertrophy and

fibrosis<sup>9,10,11,12,13,14,15,16,17</sup>. Table IV shows the most frequent ECG alterations found in patients with hypertrophic cardiomyopathy.

The clinical markers of risk are important left ventricular hypertrophy detected by echocardiography and ECG, non-sustained ventricular tachycardia by Holter ECG, poor increase of blood pressure during exercise testing, and personal history of syncope or familial sudden death. Patients with Troponin T mutation has bad prognosis even in the presence of mild left ventricular hypertrophy.

Unfortunately, there are not important ECG alterations that may differentiate this type of mutations. It has been described that patients with low voltage of QRS ( $SV_1 + RV_6 < 35$  mm) will present in the future a higher incidence of congestive heart failure, probably related with a higher degree of fibrosis. The most important problem is the differential diagnosis with athlete's heart

### **3. Arrhythmogenic dysplasia of right ventricle**

This is a genetic disease with a recessive and dominant form. Six mutations for the dominant form have been described<sup>18,19,20,21</sup>. This disease is characterized by fat infiltration of right ventricle (RV) responsible of electrical instability and risk of sudden death.

The ECG signs that suggest its presence are repolarization alterations in RV leads, especially in the presence of premature ventricular contractions with the pattern of LBBB, atypical RBBB and epsilon wave. Table V shows the incidence of all these ECG signs. ECG may be normal in 20% of cases.

### **4. Brugada syndrome.**

It is a genetically predetermined syndrome with autosomic dominant transmission and a clear incidence in young men without apparent heart disease<sup>22</sup>. Different mutations have been recently described that impair the function of ionic channels related with the gen SCN5A (chromosome 3)<sup>23</sup>. In some way LQT<sub>3</sub> syndrome and Brugada syndrome could be considered mirror images with faster inactivation in Brugada syndrome and delayed inactivation of the ionic channel in long QT<sub>3</sub> syndrome.

A family was described that had the same mutation and 2 different phenotypes: some members had LQT3 and others Brugada syndrome<sup>24</sup>

The presence of an ECG pattern in V<sub>1-3</sub> of ST elevation especially with a comb shape and frequently with a RBBB atypical pattern arises highly the suspicion of this syndrome. Characteristically the syndrome may be unmasked after the injection of drugs type I (ajmaline, etc), that block sodium channels. Sometimes the syndrome is intermittent.

Ventricular tachycardia (VT) leading to ventricular fibrillation (VF) is the most frequent cause of sudden death in patients with Brugada syndrome. The VT is usually triggered by a premature ventricular contraction of same morphology with R/T phenomenon<sup>25</sup>. The ECG pattern is related to an unbalance between I<sub>to</sub> and I<sub>Ca</sub> currents as a consequence of the ion channel mutation. This mutation increases the K current and generates the ST elevation. All the manoeuvres that increase the Ca current on the other hand decrease the ST elevation <sup>26, 27</sup>.

One of the most difficult problem is to decide if an atypical pattern such as ST ascent of early repolarization type, very frequent in athletes, due to a Brugada syndrome.

## **5. Preexcitation syndromes.**

These include the patients with anomalous AV pathway (Kent bundle) that correspond to WPW syndrome<sup>28</sup> and the patients with a bypass of AV node (short PR syndrome)<sup>29</sup>. Both cases but especially WPW syndrome may precipitate different and sometimes dangerous supraventricular arrhythmias<sup>30</sup>. It is well known that WPW syndrome may trigger in some circumstances sudden death. This is especially true in cases of rapid atrial fibrillation when an early impulse falls in the vulnerable period of ventricles and trigger ventricular fibrillation. Genetically mutations have been described in some types of WPW syndrome<sup>31</sup>. Patients with WPW at risk of sudden death usually present a fixed preexcitation and often 2 or more anomalous bundles. Baso et al<sup>32</sup> found that both syndromes represent 5% of cases of sudden death in children (4% WPW). Table 5 shows the ECG criteria of low and high risk.

## **6. AV and intraventricular blocks.**

Some congenital AV blocks and some intraventricular blocks are related with specific genetic mutation (Lenegre disease)<sup>33</sup>. Lenegre disease may be related, as other ECG patterns<sup>1</sup> with a mutation in the SCN5A gene.

## **7. Ventricular tachycardias**

We already commented that “Torsades de Pointes” type VT may be related with genetically disorders such as long QT syndrome. Recently, an atypical form of Torsades de Pointes VT with the twisting morphology of QRS but without long coupling interval and long QT has been described with some familiar incidence<sup>34</sup>. Also it has been demonstrated some genetic mutations in other forms of polymorphic VT<sup>35,36</sup>.

## **8. Conclusion.**

We know now that several ECG patterns related with risk of sudden death are genetically induced and that the ECG morphology may be different with different mutations of the same gene. Also in some circumstances an apparent normal ECG may be unmasked by some drugs or manoeuvres. The reason why in some cases of acute coronary syndrome and heart failure the premature beat may trigger sudden death, and in other cases not, may be related to subtle repolarisation changes due to genetically determined ionic channel disorders. Much probably, the importance of genetic disorders in the pathogenesis of sudden death may be much higher than what is suspected now.

However, the majority of cases of sudden death or malignant arrhythmias have not, at the moment, a genetic explanation, but there are some ECG patterns related with bad outcome and/or malignant arrhythmias are shown in table VI.

**Table I**

**ECG pattern genetically induced that suggest bad outcome including malignant arrhythmias and sudden death.**

1. Congenital long QT
2. Hypertrophic cardiomyopathy
3. Arrhythmogenic right ventricular dysplasia
4. WPW syndrome (?)
5. Brugada syndrome
6. AV and intraventricular blocks
7. Torsades de pointes
  - Typical
  - Atypical
8. Other polymorphic VT

**Tabla II**

**ECG ALTERATIONS IN CONGENITAL LONG QT SYNDROME**

1. **QT prolongation** . Qt may be normal in 5% of genetic carriers of the disease. Perform serial ECG recordings
2. **QT dispersion.** Usually clearly altered. Often is > 100 msec.
3. **Alterations in repolarization waves (fig 1).**
  - Prolonged T wave
  - Low voltage T wave or
  - Late onset T wave
  - T wave alternans
4. **Bradycardia.**
  - Generally sinus. Sometimes due to AV block 2x 1.
5. **Arrhythmias**
  - Torsades de pointes.

**Tabla III**

**DIAGNOSTIC CRITERIA IN LONG QT SYNDROME**

		Points*
1. ECG 470.	QTc 480	3
		2
	450 (var)	1
	Torsades de pointes	2
	T wave alternans or with slurrings in 3 leads	-1
	Age-dependent bradycardia	- 0,5
2. History	Sincope with stress	2
	without stress	1
	Congenital deafness	1,5
3. Family history	Relatives with congenital long QT	1
	Sudden death before 30 years in relatives	0,5

## TABLA IV

### ECG ALTERATIONS IN HYPERTROPHIC CARDIOMYOPATHY

1. **Abnormal ECG** even with near normal echocardiogram.
2. **Signs of LVH:**
  - very frequent
  - ↑ voltage QRS (otherwise doubtful)
  - Repolarization alterations. Sometimes striking (giant negative T wave – often symmetrical)
3. **Abnormal Q wave:** Rare
  - Present in leads where it does not exist normally.
  - Narrow and deep, and in general followed by positive T wave.



**Tabla V**

**ECG ALTERATIONS IN RIGHT VENTRICLE ARRHYTHMOGENIC DYSPLASIA**

–	Normal ECG	≅ 20%
–	Atypical RBBB	≅ 50%
–	Repolarization alterations (T – y/o ↑ ST)	≅ 50%
–	Peak P wave	> 10%
–	Epsilon wave	> 5%

TABLE VI

**ECG patterns not genetically induced that suggest bad outcome including  
malignant arrhythmias and sudden death**

1. Long acquired QT: ionic unbalance, post m.i. effect of drugs
2. ECG suspicious of dilated cardiomyopathy
3. Masked bifascicular block
4. Syndrome of Rosembaum
5. Appearance of RBBB during acute heart disease: (ACS and pulmonary embolism).
6. Syndrome of advanced interatrial block with retrograde left atrial activation and supraventricular arrhythmias.
7. ECG alternance (alternance of QRS and alternance of ST-T).
8. The ECG markers of bad outcome in acute phase.
9. PVC and salvos

## REFERENCES

- <sup>1</sup> Brugada R, Roberts R. Brugada syndrome: why multiple answers to a simple question?. *Circ* 2001;104:3017-19.
- <sup>2</sup> Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. *Am Heart J* 1957;54:59-68.
- <sup>3</sup> Romano C, Gemme G, Pongiglione R. Aritmie cardiache rara dell'eta' pediatrica. *Clin Pediatr* 1963;45:656-683.
- <sup>4</sup> Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carlee E. The long QT syndrome: a prospective international study. *Circulation* 1985;71:17-21.
- <sup>5</sup> Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome and the Harvey ras-1 gene. *Science* 1991;242:704-706.
- <sup>6</sup> Zareba W, Moss AJ, Schwartz PJ et al. influence of genotype on the clinical course of the long-QT syndrome. International long QT syndrome registry research group. *N Engl J Med* 1998;339:960-965.
- <sup>7</sup> Schwartz PJ, Priori SG, Locati EH et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na<sup>+</sup> channel blockade and to increases in heart rate: implications for gene-specific therapy. *Circulation* 1995;92:3381-3386.
- <sup>8</sup> Chiang Chern-En, Roden DM. los síndromes de QT largo: bases genéticas e implicaciones clínicas. *J Am Coll Cardiol* 2000;36:1-12.
- <sup>9</sup> Jarcho JA, McKenna W, Pare JA et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. *N Engl J Med* 1989;321:1372-1378.
- <sup>10</sup> Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. *Cell* 1990;62:999-1006.
- <sup>11</sup> Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. *Cell* 1994;77:701-712.
- <sup>12</sup> Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. *N Engl J Med* 1995;332:1058-1064.
- <sup>13</sup> Varnava A, Baboonian C, Davison F, et al. new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. *Heart* 1999;82:621-624.
- <sup>14</sup> Epstein ND, Cohn GM, Cyran F, et al. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene: a 908Leu-Val mutation and a 403Arg-Gln mutation. *Circulation* 1992;86:345-352.
- <sup>15</sup> McKenna WJ, Sñirito P, Desnos M, et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. *Heart* 1997;77:130-132.

- <sup>16</sup> Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two dimensional echocardiographic study of 125 patients. *Am J Cardiol* 1981;28:418-428.
- <sup>17</sup> Maron BJ, Shen WK, Link MS et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:365-372.
- <sup>18</sup> Nava A, Rossi L, Thiene G (eds). Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Elsevier, Amsterdam 1997.
- <sup>19</sup> Nava A, Thiene G, Canciani B, Scognamiglio R, Daliento R, Buja G, Martini B, Stritoni P, Fasoli G. Familial occurrence of right-ventricular dysplasia: a study involving nine families. *J Am Coll Cardiol* 1988;12:1222-1228.
- <sup>20</sup> Rampazzo A, Nava A, Danieli GA, Buja G, Daliento L, Fasoli G, Scognamiglio R, Corrado D, Thiene G. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. *Hum Mol Genet* 1994;3:959-962.
- <sup>21</sup> Rampazzo A, Nava A, Erne P, Eberhard M, Vian E, Slomp P, Tiso N, Thiene G, Danieli GA. A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 14q22-14q23. *Hum Mol Genet* 1995;4:2151-2154.
- <sup>22</sup> Brugada P, Brugada J. A distinct clinical and electrophysiologic syndrome. Right bundle branch block, persistent ST segment elevation and sudden cardiac death. A multicenter report. *J Am Coll Cardiol* 1992;20:1391-1396.
- <sup>23</sup> Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenze D, Moya A, Borggrefe M, Breithardt G, Antzelevitch Ch, O'Brien RE, Schultz-Bahr E, Keating MT, Towbin JA and Wang Q. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. *Nature* 1998;392:293-296.
- <sup>24</sup> Bezzina C, W. van den Berg MP, et al. A single Na<sup>+</sup> channel mutation causing both long-QT and Brugada syndrome. *Circ Res* 1999;85:1206-1213.
- <sup>25</sup> Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3. A marker for sudden death in patients without demonstrable structural heart disease. *Circulation* 1998;97:457-460.
- <sup>26</sup> Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko DV, Nesterenko VV, Brugada J, Brugada R, Antzelevitch C. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. *Circ Res* 1999;85:803-809.
- <sup>27</sup> Brugada R, Brugada J, Kirsch GE, Antzelevitch Ch, Potenza D, Towbin JA, Brugada P. Sodium channel blockers identify risk for sudden death in patients with ST segment elevation and right bundle branch block but structurally normal hearts. *Circulation* 2000;101:510-515.
- <sup>28</sup> Woff L, Parkinson J, White PD. Bundle branch block with short PR interval in healthy young people prone to paroxysmal tachycardia. *Am Heart J* 1930;5:686-704.
- <sup>29</sup> Torner Montoya P, Brugada P, Smeets J, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. *Eur Heart J* 1991;12:144-150.

<sup>30</sup> Bauerfeind RA, Wyndham CR, Swiryn ST et al. Paroxysmal atrial fibrillation in the Wolff-Parkinson-White syndrome. *Am J Cardiol* 1981;47:562-569.

<sup>31</sup> Doevendans PA, Wellens HJ. Wolff-Parkinson-White syndrome. A genetic disease?. *Circulation* 2001;104:3014-3016.

<sup>32</sup> Basso C, Corrado D, Rossi L, et al. Ventricular preexcitation in children and young adults: atrial myocarditis as a possible trigger of sudden death. *Circulation* 2001;103:269-275.

<sup>33</sup> Probst V, Hoorntje TM, Hulsbeek M, et al. Cardiac conduction defects associate with mutations in SCN5A. *Nat Genet* 1999;23:20-21.

<sup>34</sup> Leenhardt A, Glaser E, Burguera M, Nürnberg M, Maison-Blanche P, Coumel P. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. *Circulation* 1994;89:206-215.

<sup>35</sup> Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. *Circulation* 2001;103:485-490.

<sup>36</sup> Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia.

\* Low probability of SD:  $\leq 1$  point  
Medium probability: 2-3 points  
High probability:  $\geq 4$  points